Updates are available Correction dated 2026-02-13
Click to view Correction: https://doi.org/10.1007/s00774-025-01637-4
-
Authors
Mori, Satoshi https://orcid.org/0000-0002-7660-5562
Tanaka, Shiro
Kuroda, Tatsuhiko
Hagino, Hiroshi
Soen, Satoshi
-
Funding
Funding for this research was provided by:
Public Health Research Foundation
Asahi Kasei Pharma Corporation
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 11 June 2025
First Online: 31 July 2025
Change Date: 13 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00774-025-01637-4
Declarations
:
: S Mori has received speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., and Astellas Pharma Inc. S Tanaka has received lecture fees from MSD K.K., Datack Inc., and the Research Institute of Healthcare Data Science. He has received consultation and outsourcing fees from Eli Lilly and Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceutical K.K., and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. H Hagino received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma S Soen has received consulting fees, speaking fees, and/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. T Kuroda declares no competing interests.
